Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07631650 · ClinicalTrials.gov registry record · Phase 2
Bevonescein for Improved Intraoperative Nerve Visualization to Improve Voice Outcomes in Thyroidectomy Patients
A Phase 2 study, sponsored by Matthew Spector.
- Not yet
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT07631650 is a Phase 2 study that has not yet begun recruiting, run by Matthew Spector. The registered enrollment target is 40 participants.
The verdict
NCT07631650, a Phase 2 study, has not yet begun recruiting, sponsored by Matthew Spector.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
Bevonescein (ALM-488) is a novel fluorescein-containing peptide that is intended as a visualization adjunct for the real-time enhanced structural delineation of major nerves during Head and Neck surgery to potentially improve patient outcomes.
Interventions
- DRUG Bevonescein (ALM 488) Infusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2026-06-30 |
| Est. Completion | 2027-08-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07631650
The ClinicalTrials.gov registry entry for NCT07631650 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Matthew Spector, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Bevonescein (ALM 488) Infusion is the first listed.
NCT07631650 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07631650 about?
NCT07631650 is a clinical study titled "Bevonescein for Improved Intraoperative Nerve Visualization to Improve Voice Outcomes in Thyroidectomy Patients". Bevonescein (ALM-488) is a novel fluorescein-containing peptide that is intended as a visualization adjunct for the real-time enhanced structural delineation of major nerves during Head and Neck surgery to potentially improve patient outcomes.
What is the current status of trial NCT07631650?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2026-06-30. Estimated completion is 2027-08-31.
What interventions are being tested in trial NCT07631650?
The interventions under investigation include: Bevonescein (ALM 488) Infusion (DRUG).
Who is sponsoring clinical trial NCT07631650?
This trial is sponsored by Matthew Spector, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.